|
US5965132A
(en)
|
1992-03-05 |
1999-10-12 |
Board Of Regents, The University Of Texas System |
Methods and compositions for targeting the vasculature of solid tumors
|
|
US6749853B1
(en)
*
|
1992-03-05 |
2004-06-15 |
Board Of Regents, The University Of Texas System |
Combined methods and compositions for coagulation and tumor treatment
|
|
US7070782B1
(en)
*
|
1992-11-05 |
2006-07-04 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen
|
|
US6953668B1
(en)
|
1992-11-05 |
2005-10-11 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen
|
|
US7105159B1
(en)
*
|
1992-11-05 |
2006-09-12 |
Sloan-Kettering Institute For Cancer Research |
Antibodies to prostate-specific membrane antigen
|
|
WO1996026272A1
(en)
|
1995-02-24 |
1996-08-29 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen and uses thereof
|
|
US6569432B1
(en)
|
1995-02-24 |
2003-05-27 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen and uses thereof
|
|
US20030180290A1
(en)
*
|
1995-06-07 |
2003-09-25 |
Idec Pharmaceuticals Corporation |
Anti-CD80 antibody having ADCC activity for ADCC mediated killing of B cell lymphoma cells alone or in combination with other therapies
|
|
US20040253246A1
(en)
*
|
1996-02-23 |
2004-12-16 |
Israeli Ron S. |
Prostate-specific membrane antigen and uses thereof
|
|
US6962981B1
(en)
*
|
1996-03-25 |
2005-11-08 |
Medarex, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
|
US7381407B1
(en)
|
1996-03-25 |
2008-06-03 |
Medarex, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
|
US6107090A
(en)
|
1996-05-06 |
2000-08-22 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
|
|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
|
NZ517331A
(en)
*
|
1999-07-29 |
2004-02-27 |
Medarex Inc |
Human monoclonal antibodies to prostate specific membrane antigen and a transgenic mouse to produce the antibody
|
|
EP1710256A1
(en)
*
|
1999-07-29 |
2006-10-11 |
Medarex, Inc. |
Human monoclonal antibodies to prostate specific membrane antigen
|
|
US6379550B1
(en)
*
|
2000-07-24 |
2002-04-30 |
Health Research, Inc. |
Method for detecting PSA and its molecular forms using thiophilic gel
|
|
US6892140B1
(en)
*
|
2000-11-27 |
2005-05-10 |
Enteron, Inc. |
Immunogenic cancer peptides and uses thereof
|
|
US20020132983A1
(en)
*
|
2000-11-30 |
2002-09-19 |
Junghans Richard P. |
Antibodies as chimeric effector cell receptors against tumor antigens
|
|
CN100574803C
(zh)
*
|
2001-01-31 |
2009-12-30 |
拜奥根Idec公司 |
免疫调节抗体在治疗肿瘤性疾病中的用途
|
|
US20030103971A1
(en)
*
|
2001-11-09 |
2003-06-05 |
Kandasamy Hariharan |
Immunoregulatory antibodies and uses thereof
|
|
WO2003008537A2
(en)
*
|
2001-04-06 |
2003-01-30 |
Mannkind Corporation |
Epitope sequences
|
|
US20030007974A1
(en)
*
|
2001-05-30 |
2003-01-09 |
Nanus David M. |
Endopeptidase/anti-PSMA antibody fusion proteins for treatment of cancer
|
|
US7514078B2
(en)
*
|
2001-06-01 |
2009-04-07 |
Cornell Research Foundation, Inc. |
Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
|
|
US7666414B2
(en)
*
|
2001-06-01 |
2010-02-23 |
Cornell Research Foundation, Inc. |
Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
|
|
JP4619651B2
(ja)
*
|
2001-06-01 |
2011-01-26 |
コーネル・リサーチ・ファンデーション・インコーポレイテッド |
前立腺特異的膜抗原に対する修飾抗体およびその使用
|
|
US7671010B2
(en)
|
2002-08-30 |
2010-03-02 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
|
|
US8507445B2
(en)
|
2001-09-07 |
2013-08-13 |
Board Of Regents, The University Of Texas System |
Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
|
|
IL159422A0
(en)
*
|
2001-09-20 |
2004-06-01 |
Cornell Res Foundation Inc |
Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
|
|
US20030211075A1
(en)
*
|
2001-09-27 |
2003-11-13 |
Thorpe Philip E. |
Combined compositions for tumor vasculature coagulation and treatment
|
|
EP2360169B1
(en)
|
2001-10-23 |
2015-10-14 |
Psma Development Company, L.L.C. |
PSMA antibodies
|
|
US20050215472A1
(en)
|
2001-10-23 |
2005-09-29 |
Psma Development Company, Llc |
PSMA formulations and uses thereof
|
|
WO2003035688A2
(en)
*
|
2001-10-26 |
2003-05-01 |
Novartis Pharma Gmbh |
Targeted thrombosis by tissue factor polypeptides
|
|
US20040018519A1
(en)
*
|
2001-11-16 |
2004-01-29 |
Wright ,Jr. George L |
Methods and devices for quantitative detection of prostate specific membrane antigen and other prostatic markers
|
|
US20070031438A1
(en)
*
|
2001-12-10 |
2007-02-08 |
Junghans Richard P |
Antibodies as chimeric effector cell receptors against tumor antigens
|
|
NZ536339A
(en)
|
2002-05-08 |
2006-04-28 |
Northwest Biotherapeutics Inc |
Quality assays for antigen presenting cells
|
|
US7572442B2
(en)
|
2002-07-15 |
2009-08-11 |
Board Of Regents, The University Of Texas System |
Selected antibody compositions for binding to aminophospholipids
|
|
EP1546714A4
(en)
*
|
2002-08-30 |
2007-12-05 |
Univ Texas |
COMPOSITIONS AND METHODS FOR USE IN THE APPLICATION TO PEPTIDES FOR THE DIAGNOSIS AND THERAPY OF CANCER IN HUMANS
|
|
US9701754B1
(en)
|
2002-10-23 |
2017-07-11 |
City Of Hope |
Covalent disulfide-linked diabodies and uses thereof
|
|
US20040136998A1
(en)
*
|
2002-10-30 |
2004-07-15 |
Bander Neil H. |
Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen
|
|
ATE408712T1
(de)
*
|
2003-01-10 |
2008-10-15 |
Millennium Pharm Inc |
Verfahren zur bestimmung des wiederauftretens von prostata krebs
|
|
CA2514419A1
(en)
*
|
2003-01-28 |
2004-08-12 |
Proscan Rx Pharma Inc. |
Prostate cancer diagnosis and treatment
|
|
US20050202020A1
(en)
*
|
2004-01-09 |
2005-09-15 |
Jeffrey Ross |
Diagnosing and treating cancer
|
|
WO2005094882A1
(en)
*
|
2004-03-03 |
2005-10-13 |
Millennium Pharmaceuticals, Inc. |
Modified antibodies to prostate-specific membrane antigen and uses thereof
|
|
WO2005100404A1
(en)
*
|
2004-04-19 |
2005-10-27 |
Proscan Rx Pharma |
Prostate cancer diagnosis and treatment
|
|
ES2710439T3
(es)
*
|
2005-01-21 |
2019-04-25 |
Genentech Inc |
Dosificación fija de anticuerpos HER
|
|
CN101160324B
(zh)
*
|
2005-02-18 |
2013-04-24 |
米德列斯公司 |
缺乏岩藻糖残基的抗前列腺特异性膜抗原(psma)单克隆抗体
|
|
WO2006099175A2
(en)
*
|
2005-03-11 |
2006-09-21 |
Euro-Celtique S.A. |
Compositions comprising an anti-ca125 antibody and a cytotoxic compound and their use for the treatment of cancer
|
|
PL1868599T3
(pl)
*
|
2005-04-08 |
2010-04-30 |
Nerviano Medical Sciences Srl |
Przeciwnowotworowa kombinacja zawierająca podstawione akryloilowe pochodne dystamycyny oraz przeciwciała hamujące czynniki wzrostu lub ich receptory
|
|
LT5414B
(lt)
*
|
2005-04-13 |
2007-04-25 |
Biotechnologijos Institutas |
Monokloninių antikūnų gavimo būdas, hibridomos, gautos šiuo būdu ir rekombinantinės chimerinės į virusus panašios dalelės su įterptais kitų baltymų fragmentais kaip imunogenai hibridomų gavimui šiuo būdu
|
|
US7718775B2
(en)
*
|
2005-04-14 |
2010-05-18 |
Scinopharm Taiwan, Ltd. |
Monoclonal antibody with the capability of neutralizing enterovirus type 71 infection
|
|
EP1726650A1
(en)
*
|
2005-05-27 |
2006-11-29 |
Universitätsklinikum Freiburg |
Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
|
|
EP1996716B1
(en)
|
2006-03-20 |
2011-05-11 |
The Regents of the University of California |
Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
|
|
BE1017200A3
(nl)
*
|
2006-07-03 |
2008-04-01 |
Tekni Plex Europ Nv |
Filmstructuur met hoge zuurstofbarriere eigenschappen en werkwijze voor het vervaardigen van zulke filmstructuur.
|
|
JP2010529024A
(ja)
*
|
2007-06-01 |
2010-08-26 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
Ｃｒｉｐｔｏ結合分子
|
|
US8940298B2
(en)
|
2007-09-04 |
2015-01-27 |
The Regents Of The University Of California |
High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
|
|
WO2009046294A2
(en)
|
2007-10-03 |
2009-04-09 |
Cornell University |
Treatment of proliferative disorders using antibodies to psma
|
|
MX2010003977A
(es)
|
2007-10-12 |
2010-04-30 |
Seattle Genetics Inc |
Terapia de combinacion con conjugados de anticuerpo-farmaco.
|
|
US7678581B2
(en)
*
|
2008-01-28 |
2010-03-16 |
Clarient, Inc. |
Correlating chemical and spatial data within pathology samples
|
|
EP2281004A4
(en)
*
|
2008-04-14 |
2012-02-15 |
Proscan Rx Pharma Inc |
PROSTATE-SPECIFIC MEMBRANANT ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
|
|
EP2727606A3
(en)
|
2008-09-08 |
2015-09-23 |
Psma Development Company, L.L.C. |
Compounds for killing psma-expressing, taxane-resistant cancer cells
|
|
EP3495000A1
(en)
|
2009-02-17 |
2019-06-12 |
Cornell Research Foundation, Inc. |
Methods and kits for diagnosis of cancer and prediction of therapeutic value
|
|
MX337600B
(es)
|
2009-12-02 |
2016-03-11 |
Imaginab Inc |
Minicuerpos j591 y diacuerpos-cys para apuntar con especificidad de objetivo a un antigeno de membrana especifico para prostata de humano (psma) y metodos para su uso.
|
|
EP3501546A3
(de)
|
2011-04-21 |
2019-09-18 |
Seattle Genetics, Inc. |
Cystein-wirkstoff konjugate und ihre verwendung
|
|
SG194510A1
(en)
*
|
2011-04-22 |
2013-12-30 |
Emergent Product Dev Seattle |
Prostate-specific membrane antigen binding proteins and related compositionsand methods
|
|
MX363116B
(es)
|
2012-06-07 |
2019-03-11 |
Ambrx Inc |
Conjugados anticuerpo-farmaco de antigeno de membrana especifico de prostata.
|
|
AU2013274078A1
(en)
|
2012-06-14 |
2015-01-29 |
Ambrx, Inc. |
Anti-PSMA antibodies conjugated to nuclear receptor ligand polypeptides
|
|
ES2738310T3
(es)
|
2012-10-12 |
2020-01-21 |
Medimmune Ltd |
Pirrolobenzodiazepinas y conjugados de las mismas
|
|
CA2905181C
(en)
|
2013-03-13 |
2020-06-02 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
|
|
CA2934617A1
(en)
|
2013-12-23 |
2015-07-02 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates (adcs) with kinesin spindle protein (ksp)
|
|
US10188746B2
(en)
|
2014-09-10 |
2019-01-29 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
AU2016282723B2
(en)
|
2015-06-22 |
2021-09-23 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates (ADCs) and antibody prodrug conjugates (APDCs) with enzymatically cleavable groups
|
|
JOP20160154B1
(ar)
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
|
KR20250008141A
(ko)
|
2015-08-07 |
2025-01-14 |
이미지냅 인코포레이티드 |
분자를 표적화하기 위한 항원 결합 구조체
|
|
KR102784293B1
(ko)
|
2015-09-21 |
2025-03-20 |
압테보 리서치 앤드 디벨롭먼트 엘엘씨 |
Cd3 결합 폴리펩타이드
|
|
WO2017060322A2
(en)
|
2015-10-10 |
2017-04-13 |
Bayer Pharma Aktiengesellschaft |
Ptefb-inhibitor-adc
|
|
CN105542007A
(zh)
*
|
2016-02-03 |
2016-05-04 |
南昌大学 |
一种能特异结合前列腺特异性膜抗原胞外区的单域重链抗体
|
|
CN105524170A
(zh)
*
|
2016-02-03 |
2016-04-27 |
南昌大学 |
能特异结合前列腺特异性膜抗原的纳米抗体
|
|
CN105524169A
(zh)
*
|
2016-02-03 |
2016-04-27 |
南昌大学 |
一种能特异结合前列腺特异性膜抗原的单域重链抗体
|
|
JP7251981B2
(ja)
|
2016-03-24 |
2023-04-04 |
バイエル ファーマ アクチエンゲゼルシャフト |
酵素開裂基を有する細胞毒性活性剤のプロドラッグ
|
|
WO2017216028A1
(en)
|
2016-06-15 |
2017-12-21 |
Bayer Pharma Aktiengesellschaft |
Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
|
|
WO2018069289A1
(en)
|
2016-10-11 |
2018-04-19 |
Medimmune Limited |
Antibody-drug conjugates with immune-mediated therapy agents
|
|
WO2018114804A1
(de)
|
2016-12-21 |
2018-06-28 |
Bayer Pharma Aktiengesellschaft |
Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
|
|
KR102556826B1
(ko)
|
2016-12-21 |
2023-07-18 |
바이엘 파마 악티엔게젤샤프트 |
효소적으로 절단가능한 기를 갖는 항체 약물 접합체 (adc)
|
|
CA3047491A1
(en)
|
2016-12-21 |
2018-06-28 |
Bayer Aktiengesellschaft |
Prodrugs of cytotoxic active agents having enzymatically cleavable groups
|
|
WO2018147960A1
(en)
|
2017-02-08 |
2018-08-16 |
Imaginab, Inc. |
Extension sequences for diabodies
|
|
JP7062901B2
(ja)
*
|
2017-09-22 |
2022-05-09 |
東ソー株式会社 |
目的細胞の検出方法
|
|
SG11202010469QA
(en)
|
2018-05-23 |
2020-11-27 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
CA3103936A1
(en)
*
|
2018-06-18 |
2019-12-26 |
Eureka Therapeutics, Inc. |
Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
|
|
CN119455003A
(zh)
|
2019-02-12 |
2025-02-18 |
Ambrx公司 |
包含抗体-tlr激动剂缀合物的组合物、方法和用途
|
|
US20230372528A1
(en)
|
2020-10-16 |
2023-11-23 |
University Of Georgia Research Foundation, Inc. |
Glycoconjugates
|
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
CN117980327A
(zh)
|
2021-11-03 |
2024-05-03 |
杭州多禧生物科技有限公司 |
抗体的特异性偶联
|
|
JP2026507228A
(ja)
|
2023-03-03 |
2026-02-27 |
アーセナル バイオサイエンシズ インコーポレイテッド |
Ｐｓｍａ及びｃａ９を標的とするシステム
|